Revise protocol for conducting Phase I CT in India: CDSCO Panel Tells Biological E on Typhoid and Paratyphoid A Bivalent Vaccine
New Delhi: Reviewing the Phase I clinical trial report of Typhoid and Paratyphoid A Bivalent Vaccine conducted in Europe, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined Biological E to submit a revised protocol for the conduct of Phase I clinical trials in India.
This came after the firm presented the report of Phase I clinical trial of Typhoid and Paratyphoid A Bivalent Vaccine conducted in Europe along with revised Phase I/II clinical trial protocol titled "A prospective multicentre, observer blind, Phase I/II study to evaluate the safety and immunogenicity of Biological E's Bivalent Typhoid and Paratyphoid A conjugate vaccine when administered to healthy adults and children/adolescents infants/toddlers in India."
The committee reviewed the safety report of the Phase I clinical trial conducted in Europe.
Typhoid and paratyphoid (also known as typhoid and paratyphoid fever) are bacterial infections of the intestinal tract and bloodstream. The bacterium responsible for typhoid is called Salmonella typhi, and the bacterium responsible for paratyphoid is Salmonella paratyphi.
Earlier, the Medical Dialogue Team had reported that the committee recommended the firm to submit a complete Phase-I clinical trial report conducted in Europe for further deliberation of the proposal.
At the recent SEC meeting for vaccine held on November 26, 2024, the expert panel reviewed the report of the Phase I clinical trial of Typhoid and Paratyphoid A bivalent vaccine conducted in Europe along with the revised Phase I/II clinical trial protocol titled "A prospective multicentre, observer blind Phase I/II study to evaluate the safety and immunogenicity of Biological E's Bivalent Typhoid and Paratyphoid A conjugate vaccine when administered to healthy adults and children/adolescents infants/toddlers in India."
After detailed deliberation, the committee recommended that the firm should submit a revised protocol for the conduct of Phase I clinical trial in India to CDSCO for further deliberation.
Also Read: Intas Pharmaceutical Gets CDSCO Panel Nod To Manufacture, Market Anti-cancer Drug Pertuzumab
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.